Induced pluripotent stem cells (iPSCs) are derived from reprogrammed somatic cells by the introduction of defined transcription factors. They are characterised by a capacity for self-renewal and pluripotency. Human (h)iPSCs are expected to be used extensively for disease modelling, drug screening and regenerative medicine. Obtaining cardiac tissue from patients with mutations for genetic studies and functional analyses is a highly invasive procedure. In contrast, disease-specific hiPSCs are derived from the somatic cells of patients with specific genetic mutations responsible for disease phenotypes. These disease-specific hiPSCs are a better tool for studies of the pathophysiology and cellular responses to therapeutic agents. This article focuses on the current understanding, limitations and future direction of disease-specific hiPSC-derived cardiomyocytes for further applications.
Induced Pluripotent Stem Cells and Their Potential Applications
Induced pluripotent stem cells (iPSCs) are generated from somatic cells, such as skin fibroblasts, by ectopic expression of defined reprogramming factors. Within a few years of the first report of the generation of mouse iPSCs, several laboratories reportedly reproduced these cells using other cell types and species using similar approaches. [1] [2] [3] [4] This early attention on reproducible methods for the production of iPSCs from mammalian cells accelerated research into iPSC technology for clinical applications. iPSCs show unlimited proliferation capacity and pluripotency, as observed in embryonic stem cells (ESCs), and thus have significant advantages as a cell source for producing sufficient numbers of any cell type. In contrast with ESCs, human (h) iPSCs can be established from differentiated cells without destroying human embryos, thereby overcoming related ethical issues.
Thus, iPSCs have been extensively investigated worldwide for applications in disease modelling, drug screening and regenerative medicine ( Figure 1) . 2, 5 When hiPSCs are derived from patients with a genetic disease caused by a mutation, such patient-derived iPSCs are called disease-specific hiPSCs. As disease-specific hiPSCs contain the same genetic information as the patient, including mutations corresponding to the altered gene function, 6, 7 disease-specific hiPSCs could potentially be a powerful tool for modelling human disease. Particularly in cardiovascular research, obtaining a sufficient number of cardiomyocytes (CMs) from patients is challenging due to the highly invasive procedures required to extract them. Further, the low proliferation capacity of CMs limits researchers' ability to maintain these cells in culture. Being able to generate iPSCderived CMs (hiPSC-CMs) from a specific patient overcomes this problem, and enables identification of typical cellular responses to pathological stress and therapeutic agents because these cells potentially reflect the biological responses of an individual patient's own CMs ( Figure 1 ).
Recent genetic research has led to the identification of gene mutations responsible for hereditary heart diseases. Investigations into the pathophysiology of those inherited diseases often use animal models that partially mirror the disease conditions. However, animal studies are low throughput, time consuming and relatively expensive. Moreover, there are interspecies differences between humans and the experimental animals in terms of molecular and physiological properties (e.g. ion channel expression profile, heart rate), as well as in the cellular responses to pathological stress. Therefore, experimental results obtained from animal models do not perfectly recapitulate the conditions occurring in humans, and are less reliable for the purpose of extrapolation. In contrast, disease-specific hiPSCs could be a valuable tool in research on inherited diseases and for testing therapeutic agents.
hiPSCs are created from somatic cells, which can be easily collected from accessible patient tissues, such as skin and blood. Owing to their self-renewal property, hiPSCs could be used to produce a sufficient number of specific cell types following appropriate differentiation methods for further experiments in vitro.
Human Induced Pluripotent Stem Cells for Modelling Inherited Arrhythmias
Advances in cardiovascular research have increased our understanding of the molecular mechanisms underlying various genetic diseases.
Comprehensive genetic studies have identified causal mutations responsible for phenotypes of inherited cardiovascular diseases such as long QT syndrome (LQTS), Brugada syndrome and cardiomyopathies.
LQTS is characterised by a significantly prolonged QT interval attributable to delayed repolarisation in the ventricular myocardium.
Some types of LQTS cause life-threatening arrhythmias in response to stimuli such as swimming and sudden loud noise. Genetic studies have found a number of gene loci responsible for LQTS in families with a high incidence of the disease. Despite an absence of clinical symptoms under sedentary conditions in patients with LQTS, once ventricular tachyarrhythmias are triggered by specific stimuli, patients with LQTS are prone to exhibit syncope. Sustained arrhythmias ultimately lead to VF, resulting in sudden cardiac death. Several studies on patients with LQTS have identified a number of mutations in genes encoding cardiac ion channels, which are membrane proteins regulating the generation and propagation of action potential. [8] [9] [10] However, these mutations are not always responsible for the observed symptoms, even when the patients are exposed to the stimuli that trigger electrophysiological changes.
Effects of the stimuli or therapeutic agents, as well as the incidence of cardiac events, vary considerably among individual patients. Therefore, to address issues related to proarrhythmic mechanisms in individuals with inherited LQTS, patient-derived hiPSC-CMs with the corresponding mutation(s) could serve as powerful tools for in vitro experiments.
Previous studies characterising mutations of the alpha-subunit of the potassium voltage-gated channel subfamily Q member 1 (KCNQ1; also known as K V LQT1 and K V 7.1) using patient-derived iPSC-CMs revealed that impaired membrane trafficking of Ks channels and reduced delayed rectifier potassium channel current (I Kr ) cause LQT1. 9, 11, 12 Itzhaki et al. introduced reprogramming factors into dermal fibroblasts obtained from patients with a mutation in the alpha-subunit of potassium voltage-gated channel subfamily H member 2 (KCNH2; responsible for I Kr ) causing LQT2. 13 Spontaneously beating hiPSC-CMs carrying this mutation were used for functional analysis and exhibited a prolonged QT interval similar to that in LQTS patients.
Similar studies using hiPSC-CMs derived from a patient with a missense mutation in KCNH2 also exhibited action potential prolongation, smaller I Kr , early afterdepolarisations and arrhythmias. These changes were recovered or exaggerated by pharmacological agents or selective RNA interference in disease-specific hiPSC-CMs. [13] [14] [15] [16] Disease-specific hiPSC-CMs from patients and families with Timothy syndrome (LQT8) that have a mutation located in calcium voltage-gated channel subunit alpha1 C (CACNA1C; responsible for the L-type calcium current, I Ca,L ) have been established and assessed for mutationassociated phenotypes in vitro. 10, 17, 18 An LQT8 model using patientspecific hiPSC-CMs reflected cellular electrical abnormalities, including prolonged action potential duration, delayed afterdepolarisations and altered Ca 2+ transients. In contrast, roscovitine, an inhibitor of cyclindependent kinase 5, a key mediator involved in the regulation of Ca V 1.2 channels, enhanced I Ca,L inactivation, shortened action potential duration, restored the irregular Ca 2+ transient and decreased the frequency of abnormal depolarisations in LQT8 hiPSC-CMs. 10, 17, 18 Furthermore, other inherited arrhythmias have been investigated using disease-specific hiPSC-CMs, including various types of LQTSmutations in sodium voltage-gated channel alpha subunit 5 (SCN5A), potassium inwardly rectifying channel subfamily J member 2 (KCNJ2), calmodulin 1 (CALM1) or calmodulin 2 (CALM2), short QT syndrome (KCNH2 mutation), Brugada syndrome type 1 (SCN5A mutation) and catecholaminergic polymorphic ventricular tachycardia (mutations in ryanodine receptor 2 (RYR2) or calsequestrin 2 [CASQ2]). These cells recapitulated cellular electrophysiological changes in the heart of patients. Reduced I Ks , APD prolongation, drug-induced FPD prolongation ML277 (K V channel activator) partially restored I Ks and APD Egashira et al. 11 Ma et al. 12 KCNQ1 (R594Q, R190Q) Reduced I Ks activation, APD prolongation, abnormal subcellular KCNQ1 R190Q localisation LUF7346 (hERG modulator) normalised I Ks and APD Sala et al. 16 Isoproterenol-induced EAD was prevented by propranolol (beta-blocker)
LQT2
LQT with bifid T wave by reduced I Kr , ventricular tachyarrhythmias triggered by sudden noise at rest; higher incidence in women
Reduced I Kr , APD prolongation, EADs, triggered activity 34 Maizels et al. 36 Novak et al. 37, 38 JTB-519 (RyR stabiliser) and carvedilol suppressed abnormal Ca observed in 20-50% of patients. [42] [43] [44] Although numerous studies have summarised the characteristic features of familial heart diseases using patient-specific hiPSC-CMs, as described above, it is still challenging to fully recapitulate the disease phenotype using iPSC-CM-based disease modelling, primarily because hiPSC-CMs exhibit immature functions and morphology. For example, an incomplete ion channel profile (e.g. lack of I K1 , corresponding to slower action potential kinetics and a relatively positive diastolic potential) and subcellular structure (e.g. the absence of or underdeveloped T-tubule and sarcomere formation) are commonly observed in hiPSC-CMs. [58] [59] [60] The gene expression profile of hiPSC-CMs also resembles that of foetal CMs and is distinct from that of adult CMs. 60, 61 The immaturity of hiPSC-CMs in terms of function and gene expression profile may result in controversial findings, particularly in the investigation of late-onset cardiac diseases that largely require adult CM-like cells for disease modelling.
In an in vitro study using hiPSC-CMs to investigate the pathophysiology of late-onset Pompe disease, which is characterised by slow progression of muscle weakness, although patient-specific hiPSC-CMs exhibited typical features associated with the disease, such as intracellular glycogen accumulation and mitochondrial dysfunction, they did not fully exhibit the autophagic abnormalities that are observed in vivo. 62, 63 This may be overcome by using fully differentiated hiPSC-CMs assembled along with a complete subcellular system for muscle contraction, Ca 2+ cycling, metabolism and protein recycling. Recent studies have contributed to the development of protocols for the maturation of hiPSC-CMs using electrical and/or mechanical stimulation, a 3D culture system with scaffold materials, coculture with fibroblasts or CMs in vitro and in vivo and a combination of these techniques, leading to improvement in contractility, Ca 2+ handling and electrophysiological properties. [64] [65] [66] [67] [68] Lack of chamber-specific characteristics is another major concern regarding the use of hiPSC-CMs for disease modelling. As the structure, protocols for subtype-specific and/or chamber-specific differentiation of hiPSC-CMs will accelerate research to identify the chamber-specific phenotypes associated with heart diseases. Although some genetic heart diseases are rare, many of them lead to life-threatening conditions. Therefore, further intensive research using disease-specific hiPSC-CMs should be promoted to gain insights into the underlying mechanisms and to identify potential therapeutic targets of these genetic diseases in order to develop novel therapeutic approaches for individual patients.
Human Induced Pluripotent Stem Cells as a Tool for Drug Screening
Currently, the development of new drugs requires multiple processes, including screening of numerous putative drug compounds based on chemical structure and in vitro assays of pharmacological activity, followed by analyses of pharmacokinetics and safety in vitro and in vivo and, finally, clinical trials in humans. In most cases, these processes take many years until the candidate compounds are tested in humans. 72 current density to that in adult ventricular CMs); [12] [13] [14] 16, 71, [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] however, morphologically they are more rounded or multiangular in shape and smaller in size, with disorganised myofibrils and a lack of t-tubules, which contribute to the slower kinetics of the Ca 2+ transient. 38, 76, [83] [84] [85] [86] [87] These important differences should be considered when using hiPSCCMs in drug screening. Further investigations are needed to develop optimal methods for more efficient differentiation into functional CMs that exhibit the typical properties of adult CMs.
Gene Editing to Create Disease-Specific Human Induced Pluripotent Stem Cells
Comprehensive genetic studies have identified causal mutations responsible for genetic heart diseases. hiPSC-CMs have emerged as a highly effective tool for modelling such diseases. Although it is technically possible to induce disease-specific hiPSC-CMs, patientderived somatic cells may not be readily available, especially in the case of rare diseases. In addition, interclonal variation is seen among hiPSC clones, resulting from different genetic backgrounds associated with individual cells.
Clustered regularly interspaced short palindromic repeat (CRISPR)/ CRISPR-associated protein (Cas) 9 is a gene-editing technology that can solve the challenges associated with the genetic variability. 88, 89 CRISPR is a DNA sequence found in bacterial genomes; it is thought to be derived from viruses, is known to protect bacteria from repeated viral infections and acts as a basic adaptive immune system for prokaryotes. Cas9 is a DNA-cutting enzyme that recognises CRISPR sequences and causes site-specific DNA double-strand breaks ( Figure   2 ). Recent advances in CRISPR/Cas9-based gene editing have markedly improved the efficiency and specificity of the method and expanded its applications, including knockout, repression and activation of genes of interest. 90 In phenotypic analysis of monogenic inherited diseases, this technology is also applicable to either disease-associated mutagenesis in wildtype hiPSCs or to the correction of pathogenic gene mutations in disease-specific hiPSCs ( Figure 3) . 89 Analysis of disease-specific hiPSCs versus wild-type hiPSCs established from healthy donor cells as a control may result in unreliable outcomes due to the different genetic backgrounds of the disease-specific hiPSCs and control cells. However, CRISPR/Cas9-based gene editing enables the preparation of an isogenic control by normalising a disease-relevant mutation in disease-specific hiPSCs or by inducing the mutation in wild-type hiPSCs so that diseased Recent advances in reprogramming strategies using non-integrating, virus-free and vector-free methods are overcoming this issue. 93, 94 However, it is still technically difficult to eliminate the risk of gene mutations during the reprogramming process because forced expression of reprogramming factors can induce DNA damage. 95 In fact, protein-coding point mutations acquired during or after reprogramming were identified in multiple hiPSC lines, some of which exhibit unpredictable phenotypes. 96 Pathophysiological studies using disease-specific hiPSCs allow us to determine the cellular characteristics of a disease, but do not recreate the function of the whole organ within the body. Although complex bioengineering approaches, such as organoid formation and 3D culture systems, are available, 97, 98 it is difficult to use these methods in the heart because CMs in the heart are predominantly situated in a highly organised structure comprising vessels, nerves, mesenchymal cells, extracellular matrix and myocytes. In addition, CMs are continuously exposed to dynamically changing neuroendocrine factors and mechanical stresses. Therefore, it should be considered that studies using disease-specific hiPSC-CMs fundamentally provide simplified information regarding the pathophysiology in patients with a familial disease. Nevertheless, the experimental data from these cells may reveal responses that mirror actual phenomena in human patients, and are thus valuable for gaining an understanding of the inherited disease.
Conclusion
Disease-specific hiPSC-CMs, which carry the same genomic information as patients with inherited diseases, can undoubtedly be of use in research to address the pathophysiology of monogenic inherited diseases, the drug responsiveness of patients for personalised medicine and drug development by providing a cell source for screening compounds and drug safety testing. A combination of disease-specific hiPSC-CMs and gene-editing technologies may further advance our understanding of genetic diseases and drug development in cardiovascular medicine.
